Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $28.64 USD
Change Today +0.54 / 1.92%
Volume 218.4K
XLRN On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

acceleron pharma inc (XLRN) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/8/14 - $48.50
52 Week Low
09/9/14 - $23.61
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ACCELERON PHARMA INC (XLRN)

Related News

No related news articles were found.

acceleron pharma inc (XLRN) Related Businessweek News

No Related Businessweek News Found

acceleron pharma inc (XLRN) Details

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. The company is developing luspatercept and sotatercept therapeutic candidates, which are in Phase 3 clinical trials used to treat anemia and associated complications in patients with ß-thalassemia and myelodysplastic syndromes. The sotatercept therapeutic candidate is also used to increase bone mineral density; and to treat the final stage of chronic kidney disease and end-stage renal disease. It is also developing dalantercept therapeutic candidate to treat renal cell carcinoma and hepatocellular carcinoma; and ACE-083 that is in Phase 1 clinical trial used to promote muscle growth and function in specific treated muscle groups. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

83 Employees
Last Reported Date: 03/2/15
Founded in 2003

acceleron pharma inc (XLRN) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $460.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $325.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $335.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $392.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $335.0K
Compensation as of Fiscal Year 2014.

acceleron pharma inc (XLRN) Key Developments

Acceleron Pharma Inc. Announces Publication in Cancer Research Demonstrating Dalantercept Prevents Metastases in Preclinical Studies of Breast Cancer

Acceleron Pharma Inc. announced that new study findings involving the use of dalantercept to block the activin receptor-like kinase 1 (ALK1) pathway for the treatment of metastatic breast cancer were published in the June 15th issue (volume 75, #12) of Cancer Research, a journal of the American Association for Cancer Research. These pre-clinical findings suggest that dalantercept, in addition to treating the primary tumor, may also have an effect on metastasis, the principal clinical issue in advanced disease. The role of ALK1 expression by endothelial cells in primary breast tumor vasculature is a prognostic biomarker for metastatic dissemination. The company used dalantercept to inhibit ALK1 in multiple mouse models of breast cancer, and in doing so, the company were able to prevent metastatic dissemination and specifically the spread of the primary breast tumor to the lungs.

Acceleron Announces New Luspatercept Phase 2 Clinical Results at 20th Congress of the European Hematology Association

Acceleron Pharma Inc. announced that new preliminary results from the ongoing phase 2 clinical trials of luspatercept in patients with lower risk myelodysplastic syndromes (MDS) and in patients with beta-thalassemia were highlighted in oral presentations at the 20th Congress of the European Hematology Association in Vienna, Austria. Acceleron and its collaboration partner, Celgene Corporation, are jointly developing luspatercept. MDS Phase 2 Study: For the first time, data from the 12-month extension study of low and intermediate-1 risk myelodysplastic syndromes patients were presented. The preliminary results show encouraging longer-term, durable responses with luspatercept. Patients who completed the initial 3-month study may have been eligible to enroll in the 12-month extension study. Twenty-two patients were evaluable for efficacy analyses; 9 low transfusion burden patients and 13 high transfusion burden patients. For the low transfusion burden patients, the mean hemoglobin increase at one month was approximately 2 g/dL, increased to between 2.5 and 3.0 g/dL and was maintained for the 6-month period for which data are available. For transfused patients, 43% achieved transfusion independence with several patients maintaining this transfusion independence for more than 6 months with the longest ongoing transfusion independent patient at nearly 8 months. All of these patients remain on study. Beta-Thalassemia Phase 2 Study: Data were presented for both non-transfusion dependent (NTD) and transfusion dependent (TD) beta-thalassemia patients. The preliminary results demonstrate that luspatercept, by addressing the underlying ineffective erythropoiesis, can increase hemoglobin levels, reduce transfusion burden and reduce liver iron concentrations in iron overloaded patients. For patients who received luspatercept 0.8 "1.25 mg/kg, 38% had a mean hemoglobin increase = 1.5 g/dL maintained for at least 9 weeks. For 8 of the 12 iron overloaded NTD patients, luspatercept reduced liver iron concentration by at least 1 and up to 4.6 mg/g dry weight over the 16 week period. All ten evaluable patients who received luspatercept 0.6 "1.25 mg/kg had more than a 40% reduction in transfusion burden. For 2 of the 3 iron overloaded TD patients, luspatercept reduced liver iron concentration by 1.96 and 4.7 mg/g dry weight, respectively.

Acceleron Pharma, Inc. - Special Call

To review highlights from the two oral presentations on the luspatercept clinical trials in myelodysplastic syndromes and beta-thalassemia


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XLRN:US $28.64 USD +0.54

XLRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XLRN.
View Industry Companies

Industry Analysis


Industry Average

Valuation XLRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 59.4x
Price/Book 6.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 53.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACCELERON PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at